

Ischemic Conditioning, Endothelial Function and Enhanced External Counterpulsation: from Research Studies to Patient Care

A Focus Group Meeting at the 2013 AHA Scientific Sessions



Houston, TX AND Westbury, NY (PRWEB) October 31, 2013

Endothelix, Inc., IC Therapeutics, Inc., and Vasomedical, Inc. will be holding an invitation-only Scientific Focus Group Meeting in connection with the 2013 American Heart Association Scientific Sessions in Dallas next month. The participants will discuss state of the art science and technology related to Endothelial Dysfunction, Enhanced External Counterpulsation (EECP), Ischemic Conditioning and their potential interactions. Top researchers in each field will discuss how their research can be translated into patient care using new tools that are now available to physicians.

This invitation-only Scientific Focus Group Meeting has an unprecedented combination of topics and discussants including:

Dr. Robert Kloner; Professor of Medicine, Cardiovascular Division, Keck School of Medicine, University of Southern California, Los Angeles, CA. Director of Research, Heart Institute of Good Samaritan Hospital, Los Angeles, CA

Dr. Karin Przyklenk; Professor and Director of the Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI

Dr. Arshed Quyyumi; Professor of Cardiology, Co-Director of Emory Clinical Cardiovascular Research Institute, Department of Medicine, Emory University School of Medicine, Atlanta, GA

Dr. Christopher Wilcox; Chief of Nephrology and Hypertension, Director of Cardiovascular-Kidney Institute, Vice-Chair for Academic Affairs, Department of Medicine, George E. Schreiner Chair of Nephrology, Georgetown University Medical Center, Washington, DC

Dr. Ozlem Soran; Associate Professor of Medicine, Associate Professor of Epidemiology/Research, Director of EECF Treatment Lab, Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA

Dr. Gregory Barsness; Assistant Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

Dr. Todd Anderson; Director of Libin Cardiovascular Institute, Department Head Cardiac Science, Professor of Medicine, Department of Cardiovascular Sciences, University of Calgary, Calgary, AB, Canada

Dr. Hirofumi Tanaka; Professor of Exercise Science, Director of Cardiovascular Aging Research Laboratory, University of Texas at Austin, Austin, TX

Dr. Morteza Naghavi; Founder and President, Society for Heart Attack Prevention and Eradication (SHAPE). Chief Executive Officer, Fairway Medical Technologies, Houston, TX

Interested medical professionals are encouraged to request an invitation to this event.

About Endothelix

Endothelix, Inc. is a cardiovascular device company based in Houston, Texas and is focused on non-invasive vascular function measurement. The Company originated from the Texas Medical Center-Houston from a collaborative project between the Texas Heart Institute and The University of Texas Health Science Center at Houston. Endothelix received a \$1 million award from the Texas Emerging Technology Fund to develop the VENDYS® technology.

Endothelix's first product is VENDYS, a non-invasive, inexpensive, and easy to use vascular function test. VENDYS is FDA cleared and is currently marketed throughout the United States, Europe and Canada. The Company has a pipeline of innovative products. Additional information is available on the Company's website <http://www.endothelix.com>.

About IC Therapeutics

IC Therapeutics, Inc. is dedicated to translating the science of ischemic conditioning from research studies to patient care. Promising clinical applications of ischemic conditioning include cardiovascular diseases such as coronary artery disease, heart attack, stroke, heart failure, high blood pressure, and more. The Company is also pursuing applications of ischemic conditioning in preventive wellness care as well as improving physical and athletic performance. The Company has developed innovative techniques and medical devices to facilitate the adoption of ischemic conditioning. Additional information is available at the Company's website: <http://www.ictherapeutics.com>.

About Vasomedical:

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at <http://www.vasomedical.com>.

Contacts:

Jack B. Smyth, CEO
Endothelix, Inc.

(713) 529-2599, Jack.Smyth(at)Endothelix(dot)com

Jun Ma, CEO
Vasomedical, Inc.

(800) 455-3327, JMa(at)Vasomedical(dot)com